التداخل بين كاربيدوبا وليفودوبا وكاربيدوبا وليفودوبا وإنتاكابون

The expected incidence of fibrotic complications is so low that even if entacapone caused these complications at rates similar to those attributable to other dopaminergic therapies, it is unlikely that it would have been detected in a cohort of the size exposed to entacapone during its clinical development.